CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs
- PMID: 24850760
- DOI: 10.1182/blood-2013-12-546416
CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs
Abstract
Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population that shares certain characteristics including an aberrant myeloid phenotype and the ability to suppress T cells. MDSCs have been predominantly studied in malignant diseases and findings suggest involvement in tumor-associated immune suppression. Chronic lymphocytic leukemia (CLL) is the leukemia with the highest incidence among adults. Immune defects occur already at early disease stages and impact the clinical course. We assessed presence, frequency, association to other immune parameters, and functional properties of circulating CD14(+) cells lacking HLA-DR expression (HLA-DR(lo)) in patients with untreated CLL. These monocytic cells represent one of the best-defined human MDSC subsets. Frequency of CD14(+)HLA-DR(lo) cells was significantly increased in CLL patients. Furthermore, MDSCs suppressed in vitro T-cell activation and induced suppressive regulatory T cells (TRegs). The MDSC-mediated modulation of T cells could be attributed to their increased indoleamine 2,3-dioxygenase (IDO) activity. CLL cells induced IDO(hi) MDSCs from healthy donor monocytes suggesting bidirectional crosstalk between CLL-cells, MDSCs, and TRegs. Overall, we identified a MDSC population that expands in CLL. The exact mechanisms responsible for such accumulation remain to be elucidated and it will be of interest to test whether antagonizing suppressive functions of CLL MDSCs could represent a mean for enhancing immune responses.
© 2014 by The American Society of Hematology.
Comment in
-
MDSCs: the final frontier of the microenvironment in CLL?Blood. 2014 Jul 31;124(5):666-8. doi: 10.1182/blood-2014-06-578880. Blood. 2014. PMID: 25082859 Free PMC article.
Similar articles
-
Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.Leukemia. 2013 Feb;27(2):377-88. doi: 10.1038/leu.2012.215. Epub 2012 Jul 25. Leukemia. 2013. PMID: 22828446
-
Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.Cancer Immunol Immunother. 2015 Mar;64(3):389-99. doi: 10.1007/s00262-014-1646-4. Epub 2014 Dec 30. Cancer Immunol Immunother. 2015. PMID: 25548095 Free PMC article.
-
Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.Mol Med Rep. 2015 Jul;12(1):760-8. doi: 10.3892/mmr.2015.3374. Epub 2015 Feb 18. Mol Med Rep. 2015. PMID: 25695487
-
The CD14+HLA-DRlo/neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy.Front Immunol. 2019 May 22;10:1147. doi: 10.3389/fimmu.2019.01147. eCollection 2019. Front Immunol. 2019. PMID: 31191529 Free PMC article. Review.
-
Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia.Mol Immunol. 2019 Jun;110:77-87. doi: 10.1016/j.molimm.2017.11.014. Epub 2017 Nov 22. Mol Immunol. 2019. PMID: 29173971 Review.
Cited by
-
IDO1-Targeted Therapy Does Not Control Disease Development in the Eµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia.Cancers (Basel). 2021 Apr 15;13(8):1899. doi: 10.3390/cancers13081899. Cancers (Basel). 2021. PMID: 33920868 Free PMC article.
-
Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?Haematologica. 2016 Oct;101(10):1144-1158. doi: 10.3324/haematol.2016.145904. Haematologica. 2016. PMID: 27694502 Free PMC article. Review.
-
Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.Oncotarget. 2016 Nov 15;7(46):75407-75424. doi: 10.18632/oncotarget.12249. Oncotarget. 2016. PMID: 27705910 Free PMC article.
-
Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects.Mol Cancer. 2020 Jul 17;19(1):116. doi: 10.1186/s12943-020-01234-1. Mol Cancer. 2020. PMID: 32680511 Free PMC article. Review.
-
High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP.Front Immunol. 2024 Jan 18;14:1303959. doi: 10.3389/fimmu.2023.1303959. eCollection 2023. Front Immunol. 2024. PMID: 38304256 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous